BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15270888)

  • 1. The optimal time to determine the minimal phototoxic dose in skin photosensitized by topical 8 methoxypsoralen.
    Man I; Dawe RS; Ferguson J; Ibbotson SH
    Br J Dermatol; 2004 Jul; 151(1):179-82. PubMed ID: 15270888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
    Man I; McKinlay J; Dawe RS; Ferguson J; Ibbotson SH
    J Am Acad Dermatol; 2003 Jul; 49(1):59-64. PubMed ID: 12833009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
    Nimkulrat P; Leenutaphong V; Sudtim S
    J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity in bath-PUVA treatment.
    Tanew A; Kipfelsperger T; Seeber A; Radakovic-Fijan S; Hönigsmann H
    J Am Acad Dermatol; 2001 Apr; 44(4):638-42. PubMed ID: 11260539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythema action spectrum of topical 8-methoxypsoralen-sensitized skin re-evaluated: implications for routine clinical practice.
    Al-Ismail D; Edwards C; Anstey AV
    Br J Dermatol; 2016 Jan; 174(1):131-5. PubMed ID: 26383592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
    Grundmann-Kollmann M; Tegeder I; Ochsendorf FR; Zollner TM; Ludwig R; Kaufmann R; Podda M
    Br J Dermatol; 2001 May; 144(5):991-5. PubMed ID: 11359386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in 8-methoxypsoralen profiles during long-term psoralen plus ultraviolet A therapy and correlations between serum 8-methoxypsoralen levels and chromametric parameters.
    Marrakchi S; Decloquement L; Pollet P; Briand G; Loesche C; Bocquet JL; Degand P; Thomas P
    Photodermatol Photoimmunol Photomed; 1991 Oct; 8(5):206-11. PubMed ID: 1822684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
    Tegeder I; Bräutigam L; Podda M; Meier S; Kaufmann R; Geisslinger G; Grundmann-Kollmann M
    Clin Pharmacol Ther; 2002 Mar; 71(3):153-61. PubMed ID: 11907489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin pigmentation as a predictor of minimal phototoxic dose after oral methoxsalen.
    Bech-Thomsen N; Angelo HR; Wulf HC
    Arch Dermatol; 1994 Apr; 130(4):464-8. PubMed ID: 8166483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in 8-methoxypsoralen immersion time alters the erythemal response to bath PUVA.
    Azurdia RM; Dean MP; Rhodes LE
    Photodermatol Photoimmunol Photomed; 2000 Aug; 16(4):186-8. PubMed ID: 11019945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
    Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
    Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema.
    Cox NH; Farr PM; Diffey BL
    Arch Dermatol; 1989 Dec; 125(12):1653-7. PubMed ID: 2589859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of treatment frequency and UVA dose does not substantially compromise the antipsoriatic effect of oral psoralen-UVA.
    Legat FJ; Hofer A; Quehenberger F; Kahofer P; Kerl H; Wolf P
    J Am Acad Dermatol; 2004 Nov; 51(5):746-54. PubMed ID: 15523353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B.
    Man I; Dawe RS; Ferguson J; Ibbotson SH
    Photochem Photobiol; 2003 Jul; 78(1):55-60. PubMed ID: 12929749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?
    Beattie PE; Dawe RS; Traynor NJ; Woods JA; Ferguson J; Ibbotson SH
    Br J Dermatol; 2005 Dec; 153(6):1187-91. PubMed ID: 16307656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the minimal phototoxic dose and colorimetry in psoralen plus ultraviolet A radiation therapy.
    Kraemer CK; Menegon DB; Cestari TF
    Photodermatol Photoimmunol Photomed; 2005 Oct; 21(5):242-8. PubMed ID: 16149936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion.
    Man I; Kwok YK; Dawe RS; Ferguson J; Ibbotson SH
    Arch Dermatol; 2003 Mar; 139(3):331-4. PubMed ID: 12622625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
    Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E
    Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
    Collins P; Wainwright NJ; Amorim I; Lakshmipathi T; Ferguson J
    Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Differentiation of the antipsoriatic and phototoxic effectiveness of topical PUVA therapy].
    Meffert H; Rowe E; Miehe M; Sönnichsen N
    Hautarzt; 1986 Feb; 37(2):90-3. PubMed ID: 3957667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.